- Sancay: This is a testament to our commitment and ability to grow our portfolio companies and to realize successful exits
- AlSharekh: Successfully completing our role as a sell-side advisor marks another milestone and achievement despite the current market challenges
- Sarwat: Our current strategy is focused on monetizing investments and distributing cash to investors
Kuwait City: Kamco Invest, a regional non-banking financial powerhouse with one of the largest AUMs in the region, announced that it has successfully exited the 60% stake in Planet Pharmacies LLC, held by Kamco Invest private equity funds and co-investors, to Gulf Pharmaceutical Industries (“Julphar”) PJSC.
Since its establishment in 2007, Planet Pharmacies has experienced exponential growth with its operations expanding outside the UAE to reach Saudi Arabia and Oman. The company embarked on implementing its successful expansion strategy through acquiring a large retail chain of pharmacies, setting up new pharmacies across different cities, in addition to introducing the wholesale distribution rights of new agencies from regional and international pharmaceutical manufacturers. Despite unprecedented market conditions, the private equity team, in collaboration with the Investment Banking team at Kamco Invest, managed to successfully complete the exit on behalf of Kamco Invest funds and clients.
Ihsan Sancay, Executive Director of Private Equity at Kamco Invest said, “The exit from Planet Pharmacies, in such challenging market conditions, is a testament to our commitment and ability to grow our portfolio companies and to realize successful exits. Since initiating our joint venture with Julphar in 2007 to set up Planet Pharmacies, we played an instrumental role in expanding the company’s operations and geographic footprint, both for the retail and distribution segments, establishing Planet Pharmacies as one of the premier pharmaceutical players in the region. Our focus now lies on exploring new investments and platforms, targeting companies that are well positioned to thrive in an ever-evolving business environment. This comes in addition to forging new partnerships that aim to expand our business ecosystem.”
Abdullah AlSharekh, Managing Director of Markets and Investment Banking at Kamco Invest commented, “Successfully completing our role as a sell-side advisor marks another milestone and achievement despite the current market challenges. We are proud to be part of this successful transaction which portrays the value and growth potential of Planet Pharmacies. We look forward to successfully closing more transactions through our Mergers and Acquisitions Advisory team, who are always ready to achieve our clients’ preset objectives and deliver the best possible outcome for all our valued clients.”
Through its role, the private equity team assisted Planet Pharmacies to finalize the acquisitions since 2007, which in turn led to the enhancement of the company’s value. The company carried out internal audit review exercises, enhanced internal controls, improved reporting and financial performance dashboards, in addition to implementing operational metrics that optimized Planet Pharmacies’ capital structure to maximize shareholders’ value, amongst other value creation initiatives. These steps aided in the effective consolidation of business operations to maintain sustainable revenue streams and expand the retail and distribution network.
Sameh Sarwat, Senior Vice President of Private Equity at Kamco Invest commented, “This is one of several exits that are currently being contemplated, which falls in line with our current strategy to monetize investments and distribute cash to investors. Our exit to Julphar reflects the success of our business model that is focused on partnering with reputable strategic players and working together on implementing bespoke value creation plans to maximize the value. We look forward to progressing further our current discussions with potential partners, in order to provide our investors with off-market investments that offer attractive risk-adjusted returns.”
Roshanak Bassiri-Gharb, Corporate Legal Director at Clyde & Co in Dubai added, “We are delighted to have worked alongside the in-house teams of Kamco Invest funds and co-investors on this strategic transaction. Acting as sole external counsel together with Partner Naji Hawayek and Associate Ghalya Rashid Ali, our effective collaboration enabled us to reach a successful outcome within a particularly short timeframe. We look forward to continuing to support the group’s healthcare investment strategy across the UAE and the wider Middle East region.”
It is worth noting that Private Equity at Kamco Invest is comprised of seasoned professionals located in different countries, providing their local perspective on deals within their target regions.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
